- Home
- Publications
- Publication Search
- Publication Details
Title
Advances in acute myeloid leukemia
Authors
Keywords
-
Journal
BMJ-British Medical Journal
Volume -, Issue -, Pages n2026
Publisher
BMJ
Online
2021-10-06
DOI
10.1136/bmj.n2026
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
- (2021) David A. Sallman et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved survival of AML patients by addition of cladribine to standard induction chemotherapy
- (2020) Saša Anžej Doma et al. ANNALS OF HEMATOLOGY
- Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
- (2020) Courtney D. DiNardo et al. BLOOD
- Targeting MCL-1 in hematologic malignancies: Rationale and progress
- (2020) AndrewH. Wei et al. BLOOD REVIEWS
- Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?
- (2020) Juan Eduardo Megías-Vericat et al. BLOOD REVIEWS
- Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia
- (2020) Robert P. Hasserjian et al. BLOOD
- Supportive care in the management of patients with acute myeloid leukaemia: where are the research needs?
- (2020) Justin Loke et al. BRITISH JOURNAL OF HAEMATOLOGY
- Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2020) M. Heuser et al. ANNALS OF ONCOLOGY
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults
- (2020) Mikkael A. Sekeres et al. Blood Advances
- Acute myeloid leukemia: 2021 update on risk‐stratification and management
- (2020) Elihu H. Estey AMERICAN JOURNAL OF HEMATOLOGY
- FLT3 inhibitors in acute myeloid leukaemia: assessment of clinical effectiveness, adverse events and future research—a systematic review and meta-analysis
- (2020) S. Majothi et al. Systematic Reviews
- Gemtuzumab ozogamicin in acute myeloid leukemia: act 2, with perhaps more to come
- (2019) Johann Hitzler et al. HAEMATOLOGICA
- Targeting FLT3 mutations in AML: review of current knowledge and evidence
- (2019) Naval Daver et al. LEUKEMIA
- Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation
- (2019) Cristina Toffalori et al. NATURE MEDICINE
- Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
- (2019) Andrew H. Wei et al. JOURNAL OF CLINICAL ONCOLOGY
- An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer
- (2019) Steven Feins et al. AMERICAN JOURNAL OF HEMATOLOGY
- Current status and new treatment approaches in TP53 mutated AML
- (2019) Anthony M. Hunter et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Personalizing therapy for older adults with acute myeloid leukemia: Role of geriatric assessment and genetic profiling
- (2019) Vijaya Raj Bhatt CANCER TREATMENT REVIEWS
- Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies
- (2019) Florence Borot et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Shifting paradigms in the treatment of older adults with AML
- (2019) Thomas W. LeBlanc et al. SEMINARS IN HEMATOLOGY
- Can we predict responsiveness to hypomethylating agents in AML?
- (2019) Julia Stomper et al. SEMINARS IN HEMATOLOGY
- Efficacy and toxicity of cladribine for the treatment of refractory acute myeloid leukemia: a meta-analysis
- (2019) Anqi Zhou et al. Drug Design Development and Therapy
- Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
- (2019) Susanne Hofmann et al. Journal of Clinical Medicine
- Post-Transplant Cyclophosphamide versus Antithymocyte Globulin in HLA-Mismatched unrelated Donors transplantation
- (2019) Giorgia Battipaglia et al. BLOOD
- Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia
- (2019) Mary‐Elizabeth M. Percival et al. CANCER
- Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?
- (2019) Brian Ball et al. HAEMATOLOGICA
- Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?
- (2019) Katherine D. Cummins et al. HAEMATOLOGICA
- MRD in AML: The Role of New Techniques
- (2019) Maria Teresa Voso et al. Frontiers in Oncology
- Adoptive cell therapy using engineered natural killer cells
- (2019) Katayoun Rezvani BONE MARROW TRANSPLANTATION
- Observation versus Immediate Re-induction for Acute Myeloid Leukemia Patients with Indeterminate Day 14 Bone Marrow Results
- (2019) Omer Jamy et al. Clinical Lymphoma Myeloma & Leukemia
- Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats
- (2019) Brent A. Williams et al. Journal of Clinical Medicine
- Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer
- (2019) Yufeng Shang et al. Frontiers in Oncology
- How I treat acute myeloid leukemia in the era of new drugs
- (2019) Courtney D. DiNardo et al. BLOOD
- How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia
- (2019) Brian A. Jonas et al. LEUKEMIA
- The role of cladribine in acute myeloid leukemia: an old drug up to new tricks
- (2019) Matteo Molica et al. LEUKEMIA & LYMPHOMA
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
- (2019) Alexander E. Perl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance)
- (2019) Heidi D. Klepin et al. Journal of Geriatric Oncology
- Harnessing Natural Killer Cell Antitumor Immunity: From the Bench to Bedside
- (2019) Karrune V. Woan et al. Cancer Immunology Research
- Ready for prime time: role for geriatric assessment to improve quality of care in hematology practice
- (2019) Heidi D. Klepin BLOOD
- Reversal of T Cell Exhaustion by the First Donor Lymphocyte Infusion Is Associated with the Persistently Effective Antileukemic Responses in Patients with Relapsed AML after Allo-HSCT
- (2018) Long Liu et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation
- (2018) Sarah Cooley et al. BLOOD
- Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
- (2018) Gerrit J. Schuurhuis et al. BLOOD
- Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia
- (2018) Miriam Y. Kim et al. CELL
- Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
- (2018) Ye Li et al. Cell Stem Cell
- Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies
- (2018) Robert L. Bowman et al. Cell Stem Cell
- Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease
- (2018) Thomas A. Ollila et al. Clinical Lymphoma Myeloma & Leukemia
- Investigational CD33-targeted therapeutics for acute myeloid leukemia
- (2018) Roland B. Walter EXPERT OPINION ON INVESTIGATIONAL DRUGS
- OUP accepted manuscript
- (2018) JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
- (2018) Jeffrey E. Lancet et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
- (2018) Ying Wang et al. Journal of Hematology & Oncology
- Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms
- (2018) Anna B. Halpern et al. LEUKEMIA
- Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies
- (2018) Ann-Kathrin Eisfeld et al. LEUKEMIA
- Clonal Hematopoiesis after Induction Chemotherapy for Acute Myeloid Leukemia
- (2018) David P. Steensma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Minimal Residual Disease in Acute Myeloid Leukemia
- (2018) Mojca Jongen-Lavrencic et al. NEW ENGLAND JOURNAL OF MEDICINE
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study
- (2018) Jeffrey Wagner et al. BMJ-British Medical Journal
- Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study
- (2018) Jeffrey Wagner et al. BMJ-British Medical Journal
- Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2
- (2018) Amir T. Fathi et al. JAMA Oncology
- Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase 3 ALFA-0701 trial
- (2018) Juliette Lambert et al. HAEMATOLOGICA
- Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update
- (2018) Randy A. Taplitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia
- (2018) NEW ENGLAND JOURNAL OF MEDICINE
- Patient‐Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia
- (2018) Areej El‐Jawahri et al. ONCOLOGIST
- Will CAR T cell therapy have a role in AML? Promises and pitfalls
- (2018) Katherine D. Cummins et al. SEMINARS IN HEMATOLOGY
- The 2016 WHO classification of acute myeloid leukemia: What the practicing clinician needs to know
- (2018) Daniel A. Arber SEMINARS IN HEMATOLOGY
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
- (2018) Courtney D. DiNardo et al. BLOOD
- Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
- (2018) Jorge E. Cortes et al. LEUKEMIA
- Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies
- (2018) Megan Othus et al. LEUKEMIA
- Immune Escape of Relapsed AML Cells after Allogeneic Transplantation
- (2018) Matthew J. Christopher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial
- (2018) Nicholas J Short et al. Lancet Haematology
- Genomics of Acute Myeloid Leukemia Diagnosis and Pathways
- (2017) Lars Bullinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study
- (2017) Nancy K Gillis et al. LANCET ONCOLOGY
- Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study
- (2017) Koichi Takahashi et al. LANCET ONCOLOGY
- How good are we at predicting the fate of someone with acute myeloid leukaemia?
- (2017) E Estey et al. LEUKEMIA
- Measurable residual disease testing in acute myeloid leukaemia
- (2017) C S Hourigan et al. LEUKEMIA
- High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission
- (2017) Anna Candoni et al. LEUKEMIA RESEARCH
- Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
- (2017) Siddhartha Jaiswal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?
- (2016) Germán Campuzano-Zuluaga et al. AMERICAN JOURNAL OF HEMATOLOGY
- Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts
- (2016) S. Vasu et al. BLOOD
- How I treat FLT3-mutated AML
- (2016) Keith W. Pratz et al. BLOOD
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- TP53mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes
- (2016) Tapan M. Kadia et al. CANCER
- The urgent need to recover MHC class I in cancers for effective immunotherapy
- (2016) Federico Garrido et al. CURRENT OPINION IN IMMUNOLOGY
- Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease–Based Definition of Complete Remission?
- (2016) Daisuke Araki et al. JOURNAL OF CLINICAL ONCOLOGY
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
- (2016) Stephan Stilgenbauer et al. LANCET ONCOLOGY
- Prediction of CR following a second course of ‘7+3’ in patients with newly diagnosed acute myeloid leukemia not in CR after a first course
- (2016) M Othus et al. LEUKEMIA
- A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia
- (2016) A K Burnett et al. LEUKEMIA
- ‘CHIP’ping away at clonal hematopoiesis
- (2016) D C Link et al. LEUKEMIA
- Isocitrate dehydrogenase mutations in myeloid malignancies
- (2016) B C Medeiros et al. LEUKEMIA
- Assessment of Minimal Residual Disease in Standard-Risk AML
- (2016) Adam Ivey et al. NEW ENGLAND JOURNAL OF MEDICINE
- TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
- (2016) John S. Welch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults
- (2016) Andrew L. Young et al. Nature Communications
- Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia
- (2016) S Kayser et al. Blood Cancer Journal
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
- (2016) M. Konopleva et al. Cancer Discovery
- Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias
- (2015) Luana Fianchi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: A report from the Swedish Acute Leukemia Registry
- (2015) Erik Hulegårdh et al. AMERICAN JOURNAL OF HEMATOLOGY
- Hematopoietic stem cell transplantation for patients with AML in first complete remission
- (2015) J. J. Cornelissen et al. BLOOD
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
- (2015) D. P. Steensma et al. BLOOD
- Health care utilization and end-of-life care for older patients with acute myeloid leukemia
- (2015) Areej R. El-Jawahri et al. CANCER
- Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia
- (2015) Xueyan Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study
- (2015) Lene Sofie Granfeldt Østgård et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Significance ofNPM1Mutations in the Absence ofFLT3–Internal Tandem Duplication in Older Patients With Acute Myeloid Leukemia: A SWOG and UK National Cancer Research Institute/Medical Research Council Report
- (2015) Fabiana Ostronoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia
- (2015) A Ruggeri et al. LEUKEMIA
- Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1
- (2015) Tao Dao et al. NATURE BIOTECHNOLOGY
- Acute Myeloid Leukemia
- (2015) Hartmut Döhner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes
- (2015) Raynier Devillier et al. Oncotarget
- Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients
- (2014) Xiao-Qian Xu et al. AMERICAN JOURNAL OF HEMATOLOGY
- Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
- (2014) R. C. Lindsley et al. BLOOD
- Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells
- (2014) S. Gill et al. BLOOD
- Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation
- (2014) R B Walter et al. LEUKEMIA
- Value of routine ‘day 14’ marrow exam in newly diagnosed AML
- (2014) T Yezefski et al. LEUKEMIA
- Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
- (2014) Liran I. Shlush et al. NATURE
- Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
- (2014) Terrence N. Wong et al. NATURE
- Age-related mutations associated with clonal hematopoietic expansion and malignancies
- (2014) Mingchao Xie et al. NATURE MEDICINE
- Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
- (2014) Giulio Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
- (2014) Siddhartha Jaiswal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
- (2014) A Ehninger et al. Blood Cancer Journal
- Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug
- (2013) J. M. Rowe et al. BLOOD
- CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma
- (2013) M. Casucci et al. BLOOD
- Cell intrinsic and extrinsic factors synergize in mice with haploinsufficiency for Tp53, and two human del(5q) genes, Egr1 and Apc
- (2013) A. Stoddart et al. BLOOD
- Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008
- (2013) L. M. Morton et al. BLOOD
- Sense and nonsense of high-dose cytarabine for acute myeloid leukemia
- (2013) B. Lowenberg BLOOD
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- Recent advances in the management of therapy-related myelodysplastic syndromes and acute myeloid leukemia
- (2013) Virginia M. Klimek CURRENT OPINION IN HEMATOLOGY
- Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group
- (2013) S. Bertoli et al. HAEMATOLOGICA
- Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia
- (2013) A. H. Shih et al. HAEMATOLOGICA
- Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial
- (2013) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia
- (2013) David S. Ritchie et al. MOLECULAR THERAPY
- A No-Prophylaxis Platelet-Transfusion Strategy for Hematologic Cancers
- (2013) Simon J. Stanworth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- The Incidence of Leukemia, Lymphoma and Multiple Myeloma among Atomic Bomb Survivors: 1950–2001
- (2013) Wan-Ling Hsu et al. RADIATION RESEARCH
- Therapy-Related Myelodysplasia and Acute Myeloid Leukemia
- (2013) Smita Bhatia SEMINARS IN ONCOLOGY
- Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy
- (2013) David A. Knorr et al. Stem Cells Translational Medicine
- Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations
- (2012) Raynier Devillier et al. AMERICAN JOURNAL OF HEMATOLOGY
- Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study
- (2012) Jerzy Holowiecki et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study
- (2012) Hannes Wandt et al. LANCET
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia
- (2012) Tod A. Morris et al. LEUKEMIA RESEARCH
- Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis
- (2012) Lambert Busque et al. NATURE GENETICS
- Clonal Architecture of Secondary Acute Myeloid Leukemia
- (2012) Matthew J. Walter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study
- (2011) X. Thomas et al. BLOOD
- TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome
- (2011) F. G. Rucker et al. BLOOD
- Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia
- (2011) Pamela S. Becker et al. BRITISH JOURNAL OF HAEMATOLOGY
- Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System
- (2011) Christoph Röllig et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytarabine Dose of 36 g/m2Compared With 12 g/m2Within First Consolidation in Acute Myeloid Leukemia: Results of Patients Enrolled Onto the Prospective Randomized AML96 Study
- (2011) Markus Schaich et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study
- (2010) S. Miyawaki et al. BLOOD
- Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome
- (2010) Marcos de Lima et al. CANCER
- High Log-Scale Expansion of Functional Human Natural Killer Cells from Umbilical Cord Blood CD34-Positive Cells for Adoptive Cancer Immunotherapy
- (2010) Jan Spanholtz et al. PLoS One
- Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system
- (2009) O. K. Weinberg et al. BLOOD
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
- (2009) H. Dohner et al. BLOOD
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
- (2009) J. W. Vardiman et al. BLOOD
- Targeted Elimination of Leukemia Stem Cells; a New Therapeutic Approach in Hemato-Oncology
- (2009) B. Cate et al. CURRENT DRUG TARGETS
- Anthracycline Dose Intensification in Acute Myeloid Leukemia
- (2009) Hugo F. Fernandez et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
- (2009) Bob Löwenberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype and is associated with very poor prognosis
- (2008) D Bowen et al. LEUKEMIA
- Therapy-Related Myeloid Leukemia
- (2008) Lucy A. Godley et al. SEMINARS IN ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started